Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS (unaudited)

v3.22.2.2
CONDENSED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 4,450 $ 6,037
Restricted cash 262 295
Receivables 49 112
Inventory 460 293
Prepaid expenses and other current assets 512 480
Discontinued operations - current assets 14 12
Total current assets 5,747 7,229
Property and equipment, net 269 420
Oher assets 48 48
Operating lease right-of-use assets 212 297
Total assets 6,276 7,994
Current liabilities:    
Accounts payable 812 795
Accrued clinical trials expenses 10 9
Other accrued liabilities 557 314
Operating lease liability, current 120 112
Deferred grant revenue 261 295
Discontinued operations – current liabilities 870 1,144
Total current liabilities 2,630 2,669
Operating lease liability, noncurrent 96 187
Total liabilities 2,726 2,856
Stockholders’ equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 14,629,217 and 9,914,158 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively. 15 10
Additional paid-in capital 387,230 381,183
Accumulated deficit (383,695) (376,055)
Total stockholders’ equity 3,550 5,138
Total liabilities and stockholders’ equity $ 6,276 $ 7,994